“Why Do Some People Decline Faster Than Others With the Same Dementia?”... The Answer Is the “Brain’s Cleanup Crew” [Health Check]
- Input
- 2026-11-18 10:45:26
- Updated
- 2026-11-18 10:45:26

[Financial News] Even with the same Alzheimer's disease (AD), some patients experience a gradual decline in cognitive function, while others decline rapidly. A clue has emerged that could help estimate this difference in advance with a simple blood test.
A team led by Professor Moon Yeon-sil of the Department of Neurology at Konkuk University Hospital and Professor Kim Seung-hyun of the Department of Neurology at Hanyang University College of Medicine reported that AD progresses more rapidly when levels of the blood microRNA miR-214-3p are higher.
The research team found that as AD progresses, microglia—the brain's immune cells—become less able to clear waste, and that lower waste-clearing capacity tends to be associated with higher blood levels of miR-214-3p. The findings are considered to show the potential for this marker, which has greater predictive power than existing blood biomarkers, to help identify in advance patients at high risk of rapid progression and guide treatment and follow-up plans tailored to each patient.
The findings were published in Alzheimer's & Dementia (IF = 12.8), an international journal published by the Alzheimer's Association in the United States. The journal is regarded as one of the top international publications in the field of AD. Professor Moon and Dr. Noh Min-young of the Department of Neurology at Hanyang University College of Medicine were co-first authors, while Professor Kim and Professor Guojun Bu of the Hong Kong University of Science and Technology were corresponding authors.
At the dementia stage, the brain’s “cleanup” capacity is half that of healthy people
AD is thought to arise from the buildup of proteins such as amyloid-beta and tau in the brain. Yet even when the amount of these proteins is similar, the rate of cognitive decline varies widely from patient to patient.
The team found a possible clue to this difference in microglia, the brain's immune cells. Microglia act as the brain's “cleanup crew,” removing waste and damaged neural connections to keep the brain clean. It was already known that when this cleanup function declines, amyloid-beta can accumulate further and inflammation can worsen, potentially accelerating the disease. However, few studies had directly examined this in individual patients.
The team analyzed 114 people: 96 patients with AD, including those at the mild cognitive impairment and dementia stages, recruited from Hanyang University Medical Center, Konkuk University Hospital, and Samsung Medical Center, along with 18 healthy controls. From a single blood draw, they measured plasma markers and also cultured blood monocytes for two weeks to generate cells similar to microglia. They then compared each patient's cells for their ability to engulf waste.
The analysis showed that the cells' ability to clear waste declined as the disease progressed. The same pattern was seen with all three materials tested: amyloid-beta aggregates, fluorescent beads, and E. coli particles. At the dementia stage of AD, the median capacity to engulf amyloid-beta was half that of the control group. Expression of NCKAP1, a protein that helps cells engulf waste, also fell to about half the level in the control group.
The comparison with existing blood markers also produced a notable result. There was no significant difference in p-tau217, considered the most accurate blood marker for AD, between the mild cognitive impairment and dementia stages. By contrast, microglia's waste-clearing capacity declined further at the dementia stage.
Microglia need a protein called NCKAP1 to engulf waste. NCKAP1 rearranges the cell's cytoskeleton to form a structure that surrounds the waste. miR-214-3p is a small RNA (microRNA) predicted to suppress NCKAP1. The team therefore hypothesized that rising miR-214-3p levels could lower NCKAP1 levels and impair microglia's cleanup capacity.
In fact, miR-214-3p levels in patients' blood were highest at the dementia stage of AD. Higher blood levels of miR-214-3p tended to be associated with lower waste-clearing capacity in microglia. However, this showed only a correlation between the two measures. The study did not establish whether the miR-214-3p in the blood came from microglia or directly reduced NCKAP1 levels.
Higher miR-214-3p levels are linked to faster cognitive decline
Baseline NCKAP1 reflected only the degree of cognitive decline at the time, whereas blood miR-214-3p indicated the rate of future deterioration. Among 102 patients followed for an average of 3.2 years, higher baseline miR-214-3p levels were associated with a faster decline in scores on the Mini-Mental State Examination (MMSE). This relationship held even after accounting for age, baseline cognitive function, p-tau217, and GFAP.
When the team looked separately at 76 patients at the dementia stage of AD, miR-214-3p could distinguish patients whose disease was progressing rapidly. The team defined “rapid progression” as an annual decline of at least 4 points on the MMSE and an increase of at least 2.5 points on the Clinical Dementia Rating-Sum of Boxes (CDR-SB). When patients were divided into three groups by miR-214-3p level, none of the 26 patients in the lowest-level group progressed rapidly, compared with 2 of 25 in the middle group and 7 of 25 in the highest-level group.
Its predictive power was also substantially greater than that of existing blood biomarkers. The accuracy for distinguishing rapid progressors, measured by the area under the curve (AUC; values closer to 1 indicate greater accuracy), was 0.87 for miR-214-3p. By contrast, the values for p-tau217, a tau protein marker; GFAP, a marker of astrocyte response; and NfL, a marker of neural damage, were 0.50, 0.49, and 0.53, respectively—around 0.5. A prediction model combining age, cognitive score, and the three existing blood markers had an accuracy of 0.68; adding miR-214-3p raised it to 0.92. When recalculated using cross-validation, the value also rose from 0.24 to 0.79.
The team compared blood samples taken from the same 38 patients at two time points a median of 3.3 years apart (range: 0.4–9.4 years). Patients whose NCKAP1 levels fell more and whose miR-214-3p levels rose more over that period also experienced faster cognitive decline. By contrast, although the levels of existing blood markers (p-tau217, GFAP, and NfL) changed over time, the extent of those changes was not associated with the rate of cognitive decline.
The team said the significance of the study was that it provided grounds for explaining the mismatch between amyloid and tau accumulation and the actual rate of cognitive decline in terms of microglial dysfunction or “functional exhaustion.” Changes in microglial function could serve as a key complementary marker for understanding differences in progression from patient to patient that cannot be explained by amyloid and tau accumulation alone.
The team added that the study was observational and did not prove a causal relationship, and that only 9 of the 76 patients experienced rapid decline, so the findings need to be validated in larger follow-up studies.
Professor Moon said, “This study shows the possibility of using blood tests to estimate why the rate of progression differs from patient to patient, even among people with the same AD,” adding, “It could help develop treatment and follow-up plans tailored to individual patients in the future.”
[email protected] Jung Myung-jin, Medical Correspondent Reporter